Puma Biotechnology Stock Alpha and Beta Analysis
| PBYI Stock | USD 6.06 -0.16 -2.57% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Puma Biotechnology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Puma Biotechnology over a specified time horizon. Key technical indicators related to Puma Biotechnology's market risk premium analysis include: the following:
Beta 1.35 | Alpha 0.34 | Risk 4.47 | Sharpe Ratio 0.045 | Expected Return 0.2 |
Enterprise Value | 281.66 Million |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken.
Review Puma Biotechnology Analysis, Puma Biotechnology Valuation, Puma Biotechnology Correlation, Puma Biotechnology Hype Analysis, Puma Biotechnology Volatility, Puma Biotechnology Price History alongside Puma Biotechnology Performance for performance context on Puma Biotechnology. The set highlights volatility, risk, and valuation references.Puma Biotechnology Market Premiums
Reviewing market premium on Puma Biotechnology is useful because it places the security inside a risk-and-reward framework rather than evaluating return in isolation. The practical objective is to understand whether the position is adding rewarded risk, unrewarded volatility, or a mix of both inside the broader portfolio.| α | 0.34 | β | 1.35 |
Puma Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Puma Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how Puma Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Puma Biotechnology Market Price Analysis
Studying market price indicators for Puma Biotechnology can help investors understand whether current moves are reinforcing the thesis or signaling a weaker trading setup. Current market capitalization is about 308.31 Million, enterprise value is near 239.33 Million, and annual revenue is around 228.37 Million. Used well, these indicators can help traders refine entry and exit timing instead of reacting only to headline moves.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Aroon Oscillator | ||
| Bollinger Bands | ||
| Midpoint Price over period | ||
| Belt hold | ||
| Hanging Man |
Puma Biotechnology Return and Market Media
The median price of Puma Biotechnology for the period between Thu, Dec 11, 2025 and Wed, Mar 11, 2026 is 6.28 with a coefficient of variation of 8.91. The daily time series for the period is distributed with a sample standard deviation of 0.56, arithmetic mean of 6.3, and mean deviation of 0.45. The Stock received substantial amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 4540 shares by Maximo Nougues of Puma Biotechnology at 5.844 subject to Rule 16b-3 | 01/06/2026 |
2 | Puma Biotechnology Price Target Increased by 42.86 percent to 5.10 - Nasdaq | 02/03/2026 |
3 | Exelixis Q4 Earnings and Revenues Beat Estimates | 02/10/2026 |
4 | Acquisition by Maximo Nougues of 467 shares of Puma Biotechnology subject to Rule 16b-3 | 02/18/2026 |
5 | Puma Biotechnology Q4 2025 Earnings Preview | 02/25/2026 |
6 | Puma Biotechnology Non-GAAP EPS of 0.29 beats by 0.06, revenue of 75.5M beats by 6.9M | 02/26/2026 |
7 | Puma Biotechnology Q4 Earnings Call Highlights | 02/27/2026 |
8 | Acquisition by Maximo Nougues of 66541 shares of Puma Biotechnology at 6.68 subject to Rule 16b-3 | 03/09/2026 |
About Puma Biotechnology Performance Analysis
Puma Biotechnology performance is measured on a risk-adjusted basis against benchmarks. Risk-adjusted measures provide context for return efficiency across regimes. Puma Biotechnology shows ROE of 27.97%, ROA of 10.85%.
Unless otherwise specified, financial data for Puma Biotechnology is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Puma Biotechnology may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Puma Biotechnology Upcoming Company Events
Upcoming filing events around Puma Biotechnology deserve attention because management judgment can shape how financial strength is presented to the market. A skeptical event review can improve interpretation before the market fully absorbs the new disclosure.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Puma Biotechnology
Optimization tools can help investors judge whether capital allocated to Puma Biotechnology is being used efficiently relative to other opportunities in the same equity universe. This is most useful when investors want to improve risk-adjusted return instead of simply owning more ideas at once.
Build Diversified Portfolios
Align your risk with return expectations
More Resources for Puma Stock Analysis
A structured review of Puma Biotechnology often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Puma Biotechnology Stock. Outlined below are key reports that provide context for Puma Biotechnology Stock:Review Puma Biotechnology Analysis, Puma Biotechnology Valuation, Puma Biotechnology Correlation, Puma Biotechnology Hype Analysis, Puma Biotechnology Volatility, Puma Biotechnology Price History alongside Puma Biotechnology Performance for performance context on Puma Biotechnology. The set highlights volatility, risk, and valuation references. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Analysis related to Puma Biotechnology should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Puma Biotechnology technical stock analysis uses price and volume transformations to study behavior. Typical tools include moving averages, relative strength index, regressions, and price correlations.